287 related articles for article (PubMed ID: 1371955)
1. Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59.
Ratnoff WD; Knez JJ; Prince GM; Okada H; Lachmann PJ; Medof ME
Clin Exp Immunol; 1992 Mar; 87(3):415-21. PubMed ID: 1371955
[TBL] [Abstract][Full Text] [Related]
2. Time-dependent loss of surface complement regulatory activity during storage of donor blood.
Long KE; Yomtovian R; Kida M; Knez JJ; Medof ME
Transfusion; 1993 Apr; 33(4):294-300. PubMed ID: 7683151
[TBL] [Abstract][Full Text] [Related]
3. Preferential expression of human Fc gamma RIIIPMN (CD16) in paroxysmal nocturnal hemoglobinuria. Discordant expression of glycosyl phosphatidylinositol-linked proteins.
Edberg JC; Salmon JE; Whitlow M; Kimberly RP
J Clin Invest; 1991 Jan; 87(1):58-67. PubMed ID: 1702101
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines.
Hatanaka M; Seya T; Matsumoto M; Hara T; Nonaka M; Inoue N; Takeda J; Shimizu A
Biochem J; 1996 Mar; 314 ( Pt 3)(Pt 3):969-76. PubMed ID: 8615796
[TBL] [Abstract][Full Text] [Related]
5. Effect of glycoinositolphospholipid anchor lipid groups on functional properties of decay-accelerating factor protein in cells.
Walter EI; Ratnoff WD; Long KE; Kazura JW; Medof ME
J Biol Chem; 1992 Jan; 267(2):1245-52. PubMed ID: 1370460
[TBL] [Abstract][Full Text] [Related]
6. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
Lublin DM; Coyne KE
J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
[TBL] [Abstract][Full Text] [Related]
7. Discordant and heterogeneous expression of GPI-anchored membrane proteins on leukemic cells in a patient with paroxysmal nocturnal hemoglobinuria.
Shichishima T; Terasawa T; Hashimoto C; Ohto H; Takahashi M; Shibata A; Maruyama Y
Blood; 1993 Apr; 81(7):1855-62. PubMed ID: 7681703
[TBL] [Abstract][Full Text] [Related]
8. Heterogenous expression of decay accelerating factor and CD59/membrane attack complex inhibition factor on paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes.
Shichishima T; Terasawa T; Hashimoto C; Ohto H; Uchida T; Maruyama Y
Br J Haematol; 1991 Aug; 78(4):545-50. PubMed ID: 1716957
[TBL] [Abstract][Full Text] [Related]
9. Two distinct patterns of glycosylphosphatidylinositol (GPI) linked protein deficiency in the red cells of patients with paroxysmal nocturnal haemoglobinuria.
Hillmen P; Hows JM; Luzzatto L
Br J Haematol; 1992 Mar; 80(3):399-405. PubMed ID: 1374629
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for variations in the sensitivity of human decay accelerating factor to phosphatidylinositol-specific phospholipase C cleavage.
Walter EI; Roberts WL; Rosenberry TL; Ratnoff WD; Medof ME
J Immunol; 1990 Feb; 144(3):1030-6. PubMed ID: 1688588
[TBL] [Abstract][Full Text] [Related]
11. New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes.
Fletcher A; Bryant JA; Gardner B; Judson PA; Spring FA; Parsons SF; Mallinson G; Anstee DJ
Immunology; 1992 Mar; 75(3):507-12. PubMed ID: 1374058
[TBL] [Abstract][Full Text] [Related]
12. Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes.
Miyagawa S; Shirakura R; Matsumiya G; Nakata S; Matsuda H; Hatanaka M; Matsumoto M; Kitamura H; Seya T
Scand J Immunol; 1993 Jul; 38(1):37-44. PubMed ID: 7687071
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of paroxysmal nocturnal haemoglobinuria by phenotypic analysis of erythrocytes using two-colour flow cytometry with monoclonal antibodies to DAF and CD59/MACIF.
Shichishima T; Terasawa T; Saitoh Y; Hashimoto C; Ohto H; Maruyama Y
Br J Haematol; 1993 Oct; 85(2):378-86. PubMed ID: 7506570
[TBL] [Abstract][Full Text] [Related]
14. Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis.
Meri S; Lehto T; Sutton CW; Tyynelä J; Baumann M
Biochem J; 1996 Jun; 316 ( Pt 3)(Pt 3):923-35. PubMed ID: 8670172
[TBL] [Abstract][Full Text] [Related]
15. Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59.
Qian YM; Qin X; Miwa T; Sun X; Halperin JA; Song WC
J Immunol; 2000 Sep; 165(5):2528-34. PubMed ID: 10946279
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of mannosylglucosaminylinositol phospholipids in normal but not paroxysmal nocturnal hemoglobinuria cells.
Hirose S; Ravi L; Prince GM; Rosenfeld MG; Silber R; Andresen SW; Hazra SV; Medof ME
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):6025-9. PubMed ID: 1378620
[TBL] [Abstract][Full Text] [Related]
17. The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis.
Rosse WF; Hoffman S; Campbell M; Borowitz M; Moore JO; Parker CJ
Br J Haematol; 1991 Sep; 79(1):99-107. PubMed ID: 1716964
[TBL] [Abstract][Full Text] [Related]
18. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
19. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
Davitz MA; Low MG; Nussenzweig V
J Exp Med; 1986 May; 163(5):1150-61. PubMed ID: 2422313
[TBL] [Abstract][Full Text] [Related]
20. Paroxysmal nocturnal hemoglobinuria and glycosyl phosphatidylinositol anchored proteins that regulate complement.
Parker CJ
Clin Exp Immunol; 1991 Oct; 86 Suppl 1(Suppl 1):36-42. PubMed ID: 1718642
[No Abstract] [Full Text] [Related]
[Next] [New Search]
